XML 66 R56.htm IDEA: XBRL DOCUMENT v3.19.2
Collaborative Agreements (Details)
 1 Months Ended 3 Months Ended 6 Months Ended
Apr. 11, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 29, 2017
Aug. 07, 2015
product
Mar. 31, 2018
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Revenues             $ 135,673 $ 24,448,761 $ 2,965,579 $ 25,978,405  
Deferred grant funding             2,470,657   2,470,657   $ 4,165,848
AstraZeneca                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Revenues             62,000 1,400,000 2,800,000 2,700,000  
Collaborative Arrangement, Product | ApolloBio                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Territory expansion option period     3 years                
Proceeds received in upfront payment         $ 19,400,000            
Upfront payment received         23,000,000     23,000,000 23,000,000    
Advisory fees         960,000            
Additional revenue to be achieved                 $ 20,000,000    
Royalty period                 10 years    
Period from effective date for termination                 1 year    
Number of days written notice before termination                 90 days    
Collaborative Arrangement, Product | AstraZeneca                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Upfront payment received   $ 27,500,000       $ 27,500,000          
Anticipated development and regulatory event based payment receivable milestones                 $ 125,000,000    
Anticipated commercial event based payment receivable milestones                 115,000,000    
Number of additional products to be developed | product       2              
Deferred revenue             156,000   156,000    
Accounts receivable             78,000   78,000    
Collaborative Arrangement, Product | Coalition for Epidemic Preparedness Innovations                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Collaborative agreement, funding to be received $ 56,000,000                    
Collaborative agreement, period to receive funding for research and development 5 years                    
Funding received for research and development             1,500,000 $ 834,000 3,200,000 $ 834,000  
Deferred grant funding             $ 2,300,000   $ 2,300,000    
Foreign Tax Authority | Collaborative Arrangement, Product | ApolloBio                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Foreign corporate income taxes reducing upfront payment         2,200,000            
Foreign non-corporate income taxes reducing upfront payment         $ 1,400,000